Holen Sie sich die Stockscreener-App
13.70
12.20%
1.49
Schlusskurs vom Vortag:
$12.21
Offen:
$12.24
24-Stunden-Volumen:
23,366
Relative Volume:
0.95
Marktkapitalisierung:
$47.08M
Einnahmen:
$150.00K
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-1.9566
EPS:
-7.0019
Netto-Cashflow:
$-17.78M
1W Leistung:
-9.75%
1M Leistung:
-24.93%
6M Leistung:
+1,390%
1J Leistung:
+1.25M%
1-Tages-Spanne:
$12.00
$14.24
1-Wochen-Bereich:
$12.00
$15.29
52-Wochen-Spanne:
$0.00
$23.40
Eloxx Pharmaceuticals Inc Stock (ELOX) Company Profile
Firmenname
Eloxx Pharmaceuticals Inc
Sektor
Branche
Telefon
781-577-5300
Adresse
P.O. BOX 274, ARLINGTON
Compare ELOX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELOX
Eloxx Pharmaceuticals Inc
|
13.70 | 47.08M | 150.00K | -17.92M | -17.78M | -7.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eloxx Pharmaceuticals Inc Stock (ELOX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2026-07-20 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Eingeleitet | B. Riley Securities | Buy |
| 2020-06-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-06 | Eingeleitet | Janney | Buy |
| 2018-12-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2018-07-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Eloxx Pharmaceuticals Inc Aktie (ELOX) Neueste Nachrichten
Eloxx doses first patients in exaluren Alport trial - grafa.com
Eloxx doses first patients in Alport syndrome trial By Investing.com - Investing.com Canada
Eloxx doses first patients in Alport syndrome trial - Investing.com
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome - PR Newswire
Certain Warrants of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
Certain Stock Options of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
155,016 Common Stock of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - theglobeandmail.com
Eloxx Pharmaceuticals, Inc. Common Stock (OTC: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - kalkine.ca
Guggenheim Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Lucid Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $38 - Moomoo
Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating - Investing.com
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating By Investing.com - Investing.com India
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating - Investing.com
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - Kalkine
Eloxx Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Equity in earnings of Eloxx Pharmaceuticals, Inc. – FWB:J36 - TradingView
Eloxx Pharmaceuticals, Inc. Statistics – FWB:J36 - TradingView
J36 Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks - TradingView
Eloxx Pharmaceuticals, Inc. Common Stock (NASDAQ: ELOX) Stock Price, News & Analysis - kalkine.ca
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Eloxx Pharmaceuticals Q2 net loss widens on higher expenses - TradingView
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - Barchart.com
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering - TradingView
8-K: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary - TradingView
ELOX: Raised $58.3M in public offering, advancing exaluren trials amid rising operating losses - TradingView
Eloxx Pharmaceuticals (NASDAQ: ELOX) boosts cash with $58.3M equity raise - stocktitan.net
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks - TradingView
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
Eloxx Pharmaceuticals (ELOXD) Financials 2026Income Statement and Balance Sheet - MarketBeat
ELOXEloxx Pharmaceuticals Inc Short Interest - Finviz
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:11.940|Chg%:-0.060 - TradingKey
Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX - TradingView
ELOX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Price to earnings forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
Finanzdaten der Eloxx Pharmaceuticals Inc-Aktie (ELOX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):